Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia*

HELEN E. JO,1,2 © LAUREN K. TROY,1,2 GREGORY KEIR,3 DANIEL C. CHAMBERS,4 ANNE HOLLAND,5 NICOLE GOH,4,7 MARGARET WILSHER,6 SALLY DE BOER,6 YUBEN MOODLEY,9 CHRISTOPHER GRAINGLE,10 HELEN WHITFORD,6 SALLY CHAPMAN,11 PAUL N. REYNOLDS,11 IAN GLASPOLE,6 © DAVID BEATSON,12 LEONIE JONES,10 PETER HOPKINS4 AND TAMERA J. CORTE1,2

1Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, NSW; 2Faculty of Medicine, University of Sydney, Sydney, NSW; 3Department of Respiratory Medicine, Princess Alexandra Hospital, Brisbane, QLD; 4Department of Respiratory Medicine, The Prince Charles Hospital, Brisbane, QLD; 5Department of Physiotherapy, The Alfred Hospital, Melbourne, VIC; 6Department of Respiratory Medicine, The Alfred Hospital, Melbourne, VIC; 7Department of Respiratory Medicine, Austin Hospital, Melbourne, VIC; 8Department of Respiratory Medicine, Fiona Stanley Hospital, Perth, WA; 9Department of Respiratory Medicine, John Hunter Hospital, Newcastle, NSW; 10Department of Respiratory Medicine, Royal Adelaide Hospital, Adelaide, SA, Australia; 11Department of Respiratory Medicine, Auckland District Health Board, Auckland; 12Patient Advocate, Auckland, New Zealand

ABSTRACT

Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease (ILD) of unknown aetiology with a median survival of only 2–5 years. It is characterized by progressive dyspnoea and worsening lung function, ultimately resulting in death.

Until recently, there were no effective therapies for IPF; however, with the publication of two landmark clinical trials in 2014, the anti-fibrotic therapies, nintedanib and pirfenidone, have gained widespread approval.

This position paper aims to highlight the current evidence for the treatment of IPF, with particular application to the Australian and New Zealand population. We also consider areas in which evidence is currently lacking, especially with regard to the broader IPF severity spectrum and treatment of co-morbid conditions. The utility of non-pharmacological therapies including pulmonary rehabilitation, oxygen as well as symptom management thought to be important in the holistic care of IPF patients are also discussed.

Key words: idiopathic pulmonary fibrosis, interstitial lung disease, nintedanib, pirfenidone, treatment.

ABBREVIATIONS: 6MWD, 6-min walk distance; 6MWT, 6-min walk test; ACE, AntiCoagulant Effectiveness; AE, acute exacerbation; AE-IPF, AE of IPF; AZA, azathioprine; cHP, chronic hypersensitivity pneumonitis; CPAP, continuous positive airway pressure; CPF, combined pulmonary fibrosis and emphysema; CTD, connective tissue disease; CTD-ILD, CTD-related ILD; CTGF, connective tissue growth factor; DLCO, diffusing capacity of lung for carbon monoxide; FEV1, forced expiratory volume in 1 s; f-ILD, fibrotic ILD; FVC, forced vital capacity; GAP, gender, age and physiology; GORD, gastro-oesophageal reflux disease; IFN-Y, Interferon gamma; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; LTOT, long-term oxygen therapy; MDM, multidisciplinary meeting; MMP, matrix metalloproteinase; MUC5B, mucin 5B; NAC, N-acetylcysteine; NZ, New Zealand; OSA, obstructive sleep apnoea; PH, pulmonary hypertension; PRED, prednisolone; SDB, sleep-disordered breathing; TOLLIP, toll-interacting protein; TSANZ, Thoracic Society of Australia and New Zealand; UIP, usual interstitial pneumonia.

CONTENTS

Introduction
Methods
General measures
Pharmacological Therapy
Anti-fibrotic therapy
Therapies proven not to have effect in IPF
Anti-reflux therapy
Current and Future trials
Treatment of acute exacerbations
Treatment of co-morbidities
Non-pharmacological therapy
Oxygen
Pulmonary Rehabilitation
Lung transplant
Palliative care
Psychosocial support
Precision Medicine
Specific application to Australia and New Zealand

Correspondence: Helen E. Jo, Department of Respiratory Medicine, Royal Prince Alfred Hospital, Missenden Road, Camperdown, Sydney, NSW 2050, Australia. Email: helen.jo@sydney.edu.au

*This document has been peer reviewed by independent experts and subsequently endorsed by the Thoracic Society of Australia and New Zealand (TSANZ) in July 2017.

Received 27 July 2017; accepted 31 July 2017.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2017 The Authors
Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology
doi: 10.1111/resp.13146
INTRODUCTION

Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease (ILD) of unknown aetiology. IPF is characterized by progressive dyspnoea and worsening of lung function, ultimately resulting in death, with a median survival of only 2–5 years. While the pathogenesis remains unclear, it is likely multifactorial, with both a genetic predisposition, as well as environmental factors including smoking and industrial dust exposures thought to contribute. While the exact incidence of IPF in Australia is unknown, recent studies indicate that the prevalence of IPF is increasing globally and is estimated to be between 1.25 and 63 patients per 100,000.

The hallmark of IPF is the presence of a usual interstitial pneumonia (UIP) pattern on imaging and/or histopathology. The diagnosis of IPF can be difficult as clinical and radiological features often overlap with other ILD including chronic hypersensitivity pneumonitis (cHP), connective tissue disease-related ILD (CTD-ILD) and fibrotic nonspecific interstitial pneumonia (NSIP). There is also significant phenotypic heterogeneity within IPF, with some patients having rapidly progressive disease, and others having a more stable disease course. This complexity is acknowledged within the most recent 2011 ATS/ERS/JRS/ALAT guidelines which call for a multidisciplinary discussion to exclude other known causes of ILD and to assess for a UIP pattern on radiology and/or histology. According to these guidelines, IPF diagnosis can be categorized as ‘definite’, ‘probable’, ‘possible’ or ‘inconsistent with’ IPF, according to the presence of UIP features. The diagnosis of IPF by multidisciplinary evaluation is further discussed in detail in an accompanying position paper in this edition of the journal.

This position paper aims to highlight the current evidence for the treatment of IPF, adopted from the international guidelines on IPF treatment published in 2015, with particular application to the Australian and New Zealand (NZ) population. We also consider areas in which evidence is currently lacking, especially with regard to the broader IPF severity spectrum, as well as non-pharmacological therapies thought to be important in the holistic care of IPF patients. A suggested treatment algorithm based upon current evidence and expert opinion is also presented.

METHODS

This position paper highlights important aspects of the treatment of IPF as it pertains to Australia and NZ, and do not represent treatment guidelines per se. T.J.C. was appointed to chair a panel of 18 members, who were selected for their expertise in various aspects of IPF diagnosis and management. The expert panel was comprised of 15 respiratory physicians, 1 physiotherapist, 1 respiratory nurse as well as a patient representative (D.B.) who had opportunity to contribute to all stages of the writing process. There was widespread representation from both Australia and NZ. After an initial discussion with all authors, authors were assigned specific sections for completion. Comprehensive literature review was performed and articles for inclusion were determined by each writing group for their assigned sections and were not systematically evaluated. Where evidence was lacking, expert opinion was provided on how to address these areas. All sections, including referenced articles, were then reviewed and discussed at subsequent meetings where all authors had the opportunity to contribute to all sections.

After the completion of specific sections by assigned authors, three authors compiled and edited the complete manuscript (H.E.-A.J., P.H. and T.J.C.). All authors reviewed and approved the final manuscript. The committee did not receive any commercial sponsorship and all panel members worked on an honorary basis. This position paper is endorsed by the Thoracic Society of Australia and New Zealand (TSANZ) and will be disseminated by publication in Respirology, and via the TSANZ and Lung Foundation Australia in a collaborative pre-specified translation plan. The clinical relevance of the document will be reviewed after a maximum of 5 years.

GENERAL MEASURES

It is important to discuss general health measures with all patients with IPF, as well as their families, to ensure active engagement. The management of IPF patients involves many health professionals including the respiratory physician, IPF nurses, pharmacists, physiotherapists and other allied health professionals, as well as palliative care and transplant teams. As such, the patient’s local general practitioner plays a vital role in the coordination of care of these patients and should be involved at all stages.

The comprehensive management of patients with IPF, therefore, involves not only the consideration of IPF-specific pharmacological therapies for disease management but also the management of other comorbidities, disease-related symptoms, overall general health as well as patient education. While specific evidence for the management of general health measures is lacking in IPF, these global health factors can have implications beyond IPF disease. For example, it is important for patients to maintain good nutrition and a healthy body weight as this is often a consideration for transplant eligibility. Smoking cessation is also important in that regard and also has implications regarding the use of long-term oxygen therapy (LTOT). Smoking has also been shown to decrease systemic exposure to both nintedanib and pirfenidone and smoking cessation should be strongly advised when initiating either of these medications.

Depression and anxiety are other common but often overlooked co-morbidities in IPF patients, associated with a poorer quality of life and poorer outcomes. Underlying depression and anxiety are often correlated with the presence of debilitating symptoms such as dyspnoea, a symptom affecting up to 90% of patients at diagnosis. Depression and anxiety may also be exacerbated by medication side effects, acute exacerbations.
(AE) and deterioration requiring hospital admission, as well as fear associated with the overall poor prognosis in IPF. There are no controlled studies addressing the management of depression and/or anxiety in IPF patients.

**PHARMACOLOGICAL THERAPY**

**Anti-fibrotic therapy**

Until recently, no effective therapies were available for IPF. However, following a number of landmark clinical trials (Table 1), nintedanib and pirfenidone are now recommended for the treatment of IPF in the updated multinational clinical practice guidelines, and are licensed for the treatment of IPF in an increasing number of countries. Figure 1 suggests an algorithm for the management of patients with IPF.

**Pirfenidone**

Pirfenidone is a novel anti-fibrotic agent, and while its precise molecular target remains unknown, it exhibits pleiotropic anti-fibrotic actions via several pathways. The first human clinical trial of pirfenidone in IPF was reported in 1999, and since that time, it has been evaluated in four phase 3 randomized controlled trials. Taniguchi et al. initially reported reduced decline in vital capacity and improved progression-free survival in 275 Japanese patients, and this was followed by two concurrent multinational studies (CAPACITY® 004 and 006) involving 779 patients in the USA, Europe and Australia. In the positive 004 study, high-dose pirfenidone (2403 mg/day) was associated with a significantly reduced mean decline in percentage predicted forced vital capacity (FVC) compared with placebo at week 72 (−8.0 ± 16.5% and −12.4 ± 18.5%, respectively; \(P = 0.001\)). While the 006 study was negative (with a decline in mean FVC of −9.0 ± 19.6% and −9.6 ± 19.0% in the pirfenidone and placebo arms, respectively; \(P = 0.5\)), the pre-specified pooling of the study data demonstrated a significant effect of pirfenidone (2403 mg/day) in reducing the rate of decline in FVC.

While the European Medicines Agency approved pirfenidone for use in IPF in 2011, regulatory authorities in the US requested additional trial data. The ASCEND® study confirmed the positive effect of pirfenidone, with a relative reduction of 47.9% in the proportion of patients who had an absolute decline of FVC ≥ 10% predicted, or who died, at week 52. A pre-specified survival analysis (including data from the CAPACITY® and ASCEND® studies), demonstrated a reduction in all-cause and IPF-related mortality (hazard ratio: 0.35; \(P = 0.03\)). Subgroup analysis (using pooled data from both CAPACITY® and ASCEND® studies) demonstrated the treatment effect of pirfenidone to be generally consistent across all demographic variables and baseline measures of IPF disease severity. An analysis of safety outcomes for the CAPACITY® and ASCEND® studies, including 1299 patients with a median duration of pirfenidone exposure of 1.7 years (range: 1 week–9.9 years), reported nausea (37.6%), diarrhoea (28.1%), dyspepsia (18.4%), vomiting (15.9%) and photosensitive rash (25%) as the most common adverse events, although these were generally mild and without significant clinical consequences. Nausea and rash were the adverse events most commonly associated with treatment discontinuation in 1.7% and 1.5% of patients, respectively. Particularly relevant to the Australian and NZ climate is the risk of photosensitivity, and patients should be counselled regarding the avoidance of direct sunlight exposure.

**Nintedanib**

Nintedanib (formally known as BIBF 1120), an intracellular inhibitor of tyrosine kinases, attenuates fibrosis via several mechanisms, including reduction in fibroblast proliferation and differentiation of fibroblasts to myofibroblasts. In a randomized, double-blind, placebo-controlled phase 2 dose finding study (TOMORROW®-1), 431 patients were assigned to various nintedanib doses (50, 100 and 150 mg daily, and 150 mg twice daily (bd)) or placebo for 52 weeks. Compared with placebo, nintedanib 150 mg bd was associated with reduced decline in FVC, a reduction in investigator-reported AE of IPF (AE-IPF) and preservation of health-related quality of life.

Subsequently, in two replicate randomized, double-blind, placebo-controlled phase 3 studies (INPULSIS®-1 and INPULSIS®-2), 1066 patients were assigned in a 3:2 ratio to receive nintedanib (150 mg bd) or placebo. Compared with placebo, nintedanib was associated with a reduced annual rate of FVC decline in both trials (with a difference of 125.3 mL/year; 95% CI: 77.7–172.8; \(P < 0.001\) in INPULSIS®-1 and 93.7 mL/year; 95% CI: 44.8–142.7; \(P < 0.001\) in INPULSIS®-2). In a key secondary end point, there was a reduction favouring nintedanib in time to first investigator-reported AE-IPF in INPULSIS®-1 but not INPULSIS®-2, but when AE-IPF were centrally adjudicated, there was a significant reduction favouring nintedanib in the pooled data set. In a pre-specified analysis, the effect of nintedanib on annual rate of decline in FVC was similar across a range of subgroups, irrespective of age, gender, baseline FVC severity or smoking status. Furthermore, in patients with a possible pattern of UIP with traction bronchiectasis on HRCT (but without a surgical lung biopsy), the treatment effect of nintedanib was similar to patients with honeycombing on HRCT and/or confirmation of UIP on surgical lung biopsy.

The most frequent adverse event in the nintedanib groups was diarrhoea (with rates of approximately 60%), which resulted in cessation of the drug in <5% of patients. Other common adverse events included nausea, vomiting and decreased appetite, occurring in 8–25% of patients.

**Clinical experience with anti-fibrotic medications**

There is increasing data for the use of both pirfenidone and nintedanib emerging from single centres and larger IPF registries, with findings broadly consistent with...
### Table 1  Randomized controlled trials in idiopathic pulmonary fibrosis

| Study | Year | Intervention | Mode of action | n  | Duration (weeks) | Primary outcome | Result  |
|-------|------|--------------|---------------|----|-----------------|----------------|---------|
| **Anti-fibrotic medications** |      |              |               |    |                 |                |         |
| Azuma *et al.* 8 | 2005 | Pirfenidone  | Anti-fibrotic  | 107| 63              | SpO₂ change on 6MWT | NEG    |
| Taniguchi *et al.* 9 | 2010 | Pirfenidone  | Anti-fibrotic  | 275| 52              | VC change       | POS    |
| CAPACITY® 004 and 006 10 | 2011 | Pirfenidone  | Anti-fibrotic  | 779| 72              | FVC change      | POS    |
| TOMORROW® 11 | 2011 | Nintedanib   | Anti-fibrotic  | 432| 52              | FVC change      | POS    |
| INPUTULSIS®-1 and -2 12 | 2014 | Nintedanib   | Anti-fibrotic  | 1066| 52             | FVC change      | POS    |
| ASCEND® 13 | 2014 | Pirfenidone  | Anti-fibrotic  | 555| 52              | FVC change      | POS    |
| **Pulmonary vasodilators** |      |              |               |    |                 |                |         |
| BUILD®-1 14 | 2008 | Bosentan     | Pulmonary vasodilator | 158| 52                  | 6MWD change | NEG    |
| STEP-IPF® 15 | 2010 | Sildenafil   | Pulmonary vasodilator | 180| 12                  | 6MWD > 20% improvement | NEG    |
| BUILD®-3 16 | 2011 | Bosentan     | Pulmonary vasodilator | 616| 52                  | Disease progression | NEG    |
| ARTEMIS-IPF® 17 | 2013 | Ambrisentan  | Pulmonary vasodilator | 492| 35                  | Death, hospitalization, disease progression | NEG    |
| MUSIC® 18 | 2013 | Macitentan  | Pulmonary vasodilator | 178| 52                  | FVC change | NEG    |
| **Antioxidants** |      |              |               |    |                 |                |         |
| IFIGENIA® 19 | 2005 | NAC (background prednisone, AZA) | Antioxidant | 182| 52                      | FVC change, DL CO change | POS    |
| Homma *et al.* 20 | 2012 | Inhaled NAC  | Antioxidant   | 76 | 48                    | FVC change | NEG    |
| PANTHER® 21 | 2014 | NAC          | Antioxidant  | 264| 60                    | FVC change | NEG    |
| **Immunomodulation** |      |              |               |    |                 |                |         |
| Raghu *et al.* 22 | 2004 | IFN-Y        | Immunomodulation | 330| 58                  | Disease progression | NEG    |
| Raghu *et al.* 23 | 2008 | Etanercept   | Immunomodulation | 88 | 48                  | FVC DL CO and P(A-a)O₂ change | NEG    |
| INSPIRE® 24 | 2009 | IFN-Y        | Immunomodulation | 826| 64                  | Mortality | NEG    |
| Daniels *et al.* 25 | 2010 | Imatanib     | Immunomodulation | 119| 96                  | Disease progression | NEG    |
| **Combination treatments** |      |              |               |    |                 |                |         |
| PANTHER® 26 | 2012 | Prednisone, AZA, NAC | Immunomodulation and antioxidant | 155| 32                    | FVC change | Harmful |
| PANORMA® 27 | 2016 | Pirfenidone and NAC | Anti-fibrotic and antioxidant | 123| 24                    | FVC, DL CO and 6MWT change | NEG    |
| **Other** |      |              |               |    |                 |                |         |
| Horton *et al.* 28 | 2012 | Thalidomide  | Anticoagulant | 24 | 12                      | Cough | POS    |
| ACE-IPF® 29 | 2012 | Warfarin     | Anticoagulant | 145| 28                      | Death, hospitalization, FVC 10% | NEG    |

---

*Overall pooled results were positive, although CAPACITY® 006 was negative for primary outcome.
6MWD, 6-min walk distance; 6MWT, 6-min walk test; ACE, AntiCoagulant Effectiveness; AZA, azathioprine; DLCO, diffusing capacity of lung for carbon monoxide; FVC, forced vital capacity; IFN-Y, Interferon gamma; IPF, idiopathic pulmonary fibrosis; NAC, N-acetylcysteine; NEG, negative; P(A-a)O₂, Alveolar-arterial gradient for oxygen; POS, positive; SpO₂, oxygen saturation; VC, vital capacity.

**Note:** Refer to the original publication for comprehensive details and references.
clinical trial data. PASSPORT®, a prospective, observational long-term registry, was established in 2011 following the approval of pirfenidone by the European Medicines Agency. Following interim analysis of the first 530 patients (who had received at least one dose of pirfenidone), the PASSPORT® investigators have concluded that the longer term safety profile of pirfenidone is consistent with that seen in clinical trials, and no new or unexpected safety signals have emerged.37

INPULSIS®-ON is a single-arm extension study in which patients participating in the INPULSIS® studies then received open label treatment with nintedanib.38 Interim analysis demonstrated that the beneficial effect of nintedanib in decreasing disease progression was maintained over 2 years, and long-term treatment with nintedanib had a manageable safety and tolerability profile similar to that seen in the initial INPULSIS® studies.

Numerous single centre experiences39–42 have reported similar findings with regard to treatment efficacy and safety profile, including successful management of side effects and acceptable but higher discontinuation rates in ‘real-world’ populations who were older with more severe lung function impairment and co-morbidities compared with clinical trial populations.42

Combination therapy
There are little data on the combination of pirfenidone and nintedanib to date. Since they have different mechanisms of action, it has been postulated that combination may induce a greater reduction in FVC decline. In a small group of 50 patients, Ogura et al.43 conducted a randomized, double-blind, phase 2, dose escalation trial to assess the safety, tolerability and pharmacokinetics of nintedanib, alone and in combination with pirfenidone. Overall, while the patients on combination therapy reported slightly higher rates of nausea and vomiting, adverse events were mostly mild to moderate with the authors concluding that combination therapy had an acceptable safety and tolerability. There are two ongoing studies currently assessing combination treatment in IPF.44

Practical questions with regard to anti-fibrotic therapy
While clinical trials (with clearly defined inclusion and exclusion criteria) provide broad guidelines as to who may benefit from anti-fibrotic therapy, in real-world clinical practice, deciding which drug to use, when and in whom is not often as straightforward. Both pirfenidone and nintedanib appear to have similar efficacy in reducing FVC decline, and while a mortality benefit has been demonstrated with pirfenidone, nintedanib has been shown to reduce adjudicated AE-IPF. The substantially different side effect profile for each drug, compliance with tablet medications, medication interactions and patient preference are likely to be key factors in deciding which agent to use.

Evidence supporting early initiation of treatment has recently been published, with both nintedanib and pirfenidone demonstrating similar treatment efficacy irrespective of baseline lung function severity, suggesting a beneficial effect of anti-fibrotic therapy even in patients with well-preserved physiology.45,46 There is also evidence from small studies to suggest that patients with a more rapid decline in the months prior to therapy with pirfenidone may have better attenuation of FVC decline.47–49
While IPF disease heterogeneity is increasingly recognized, tools for predicting disease behaviour in individual patients (in particular, identifying those at risk of progressive disease) remain frustratingly imprecise. A focus on ‘personalized medicine’ and predictive biomarkers in IPF may provide vital information in identifying patients at risk for progressive disease in the future, although such information is not currently routinely available.45,46

Despite therapeutic intervention with anti-fibrotic agents, it is likely that patients with IPF will continue to experience disease progression. Pooled data from the CAPACITY® and ASCEND® studies suggest that in patients who progress on pirfenidone (defined as a decline in FVC of ≥10% during a 6-month period), continued treatment with pirfenidone resulted in a lower risk of subsequent FVC decline or death.50 Similar data are available for nintedanib.51 With the availability of two proven therapies, some patients and clinicians will opt for switching treatment in the event of disease progression, although little evidence exists to support or refute this approach.

Summary

- In the 2015 multinational IPF treatment guidelines,4 both nintedanib and pirfenidone received positive treatment recommendations for IPF. Consistent with these recommendations, in patients with a multidisciplinary confirmed diagnosis of IPF of mild to moderate severity, monotherapy with either pirfenidone or nintedanib should be considered as first-line therapy.
- The choice of anti-fibrotic agent should be individualized to the patient according to their co-morbidities and likely tolerability of either medication.

Treatment of IPF patients with varying disease severity

There is no universal consensus on how to define disease severity of IPF patients, with several different methods including baseline FVC, diffusing capacity of lung for carbon monoxide (DLCO), GAP (gender, age and physiology) index,52 composite physiological index (CPI)53 and Japanese disease severity classification (JSC)54 described. Whilst there is some difficulty using a single measure of FVC to judge severity of impairment in the clinical setting where a premorbid value is often unknown, it has been widely accepted as a measure of disease progression and despite its failings, has been repeatedly used as a primary outcome measure for clinical trials.55

Very mild asymptomatic disease. It is currently unclear whether patients with very mild, asymptomatic disease would benefit from anti-fibrotic treatment as there are no specific randomized controlled trials in this group. In a post hoc analysis of the pooled INPULSIS® data, patients with FVC > 90% predicted were found to have the same rate of FVC decline as those with FVC ≤ 90%,46 as did the patients stratified by FVC > 80% or GAP stage 1 disease in the pooled ASCEND®/CAPACITY® cohorts.45 Treatment with anti-fibrotic medications appeared to attenuate progression of IPF to the same degree in these mild cohorts as they did in the more severe groups. While these data appear to support the use of anti-fibrotic medications in this cohort, these are post hoc analyses and it is yet to be determined whether these results translate into meaningful clinical benefit, especially in patients who have preserved and stable lung function. In this cohort with mild, asymptomatic disease, the decision to treat should be individualized, taking into consideration the patient’s age, co-morbidities and potential side effects of treatment.

Mild to moderate disease. In this population with mild-to-moderate IPF, there is currently the most data for treatment with anti-fibrotic medications. All major anti-fibrotic clinical trials have required an FVC ≥ 50% for inclusion, with the ASCEND® trial alone stipulating an upper limit of ≤90%. The mean FVC was higher in the nintedanib (78.1–80.5%) than the pirfenidone trials (ASCEND® mean FVC: 67.8%, CAPACITY® mean FVC: 74.4–76%). In the recent international consensus guidelines, treatment of this group with anti-fibrotic medications was given a conditional positive recommendation.4 This mild-to-moderate IPF cohort is also the group that funding bodies in some countries have chosen for government-funded anti-fibrotic therapy.

Severe disease. There is very little evidence to guide clinicians with regard to treatment of patients with severe IPF, as this cohort of patients was systematically excluded from all large controlled trials. There have been a number of small real-world cohort studies suggesting that those with more severe disease may actually have greater benefit from pirfenidone with a similar rate of adverse events.47–49,56 A controlled study using nintedanib in severe IPF is currently recruiting patients globally (NCT02802345). Further data are required before any suggested management recommendations can be made with regard to anti-fibrotic agents in severe IPF. Local prescribing restrictions have prohibited the use of anti-fibrotic agents in severe disease in many countries until more data are available.

Definite versus probable and possible IPF

In clinical practice, there are often patients in whom a definite IPF diagnosis cannot be secured, usually due to atypical imaging and lack of a surgical lung biopsy. Surgical lung biopsy is not without risk and many patients with IPF have co-morbidities precluding a biopsy or elect not to consent to the procedure.57 In such patients, a definite diagnosis of IPF cannot be confirmed and are given a pragmatic diagnosis of probable or possible IPF without lung biopsy. There has been growing support for this pragmatic approach with several studies showing that a UIP pattern on histopathology is often confirmed at surgical lung biopsy in patients with possible IPF.58–61

It is likely those with possible IPF have the potential to benefit from treatment with anti-fibrotic therapy, 31.9% of the patients enrolled in the INPULSIS® trials
had possible UIP with traction bronchiectasis on HRCT, without a surgical lung biopsy. A post hoc analysis of data from these studies demonstrated that these patients have disease progression and treatment response no different from those with definite UIP.\(^{30}\) Small retrospective cohort studies of pirfenidone also suggest treatment equivalence.\(^{49,62}\)

**UIP pattern in non-IPF disease and unclassifiable ILD**

While IPF frequently presents with a UIP pattern on HRCT, a UIP pattern does not exclusively represent a diagnosis of IPF. Other fibrosing ILD including CTD-ILD, chP and asbestosis can also present with a UIP pattern on HRCT and/or histopathology and thus may incorrectly be diagnosed as IPF. Given that treatment of these conditions differs considerably from IPF, it is crucial that any patient with a fibrosing ILD undergo a thorough assessment including a detailed history of environmental exposures as well as specific questioning for subtle symptoms and signs of a CTD.\(^{63}\) Evaluation of autoantibodies as well as serum precipitins should also be considered in a compatible clinical context.\(^{64}\) The use of bronchoscopy and bronchoalveolar lavage is debated and should be considered on an individual basis.\(^{1}\) All patients should undergo an ILD multidisciplinary meeting (MDM) with physicians, radiologists and histopathologists specialized in ILD present, as subtle features that may help differentiate these conditions may be present. Despite the biological plausibility for the use of anti-fibrotic agents in patients with non-IPF UIP, there are no current data to support this practice.

However, despite thorough investigation and discussion at an ILD MDM, a significant minority of patients with ILD remain unclassifiable.\(^{65,66}\) This is often due to the absence of, or inadequate histopathology, as well as conflicting clinical, radiological and histopathological data. While there is no consensus definition of ‘unclassifiable ILD’, this group is likely to be heterogeneous, reflected by their overall prognosis which lies between IPF and non-IPF ILD.\(^{65}\) While there may be biological plausibility for efficacy of anti-fibrotic therapy in these ‘unclassifiable’ fibrosing ILD there is no current evidence to support their use. There are ongoing clinical studies with both pirfenidone and nintedanib recruiting unclassifiable ILD and progressive fibrosing ILD patients, respectively.

**Summary**

- Anti-fibrotic therapy appears to have similar efficacy in decreasing disease progression in patients with both mild and moderate disease severity.
- The overall treatment benefit in very mild, asymptomatic disease is unknown and treatment should be considered on an individual basis.
- Despite biological plausibility, there is no controlled evidence to support the use of anti-fibrotic therapy for IPF patients with severe disease or those with non-IPF UIP or unclassifiable ILD. Such patients should be encouraged to enrol in clinical trials.

**Therapies proven not to have effect in IPF**

IPF clinical trials have historically suffered from two major problems: first, older studies included patients who would now not be considered to have true IPF; and second, small initial investigations reported positive outcomes, but these findings were not replicated in larger, appropriately powered studies. The randomized controlled trials that have been performed, as well as their overall outcomes, are summarized in Table 1. As demonstrated by this table, there have been a number of trials, particularly with the use of immunomodulation, pulmonary vasodilators and N-acetylcysteine (NAC) which have had disappointing results.

The use of combination prednisolone (PRED), azathioprine (AZA) and NAC in IPF, as well as anticoagulation, offer useful lessons regarding interpretation of data on which clinical ‘best practice’ is based. Although the small initial trials of these therapies were promising, larger, appropriately powered trials demonstrated not only lack of efficacy, but also increased harm.

**Combination PRED, AZA and NAC**

For many years, the standard of care for IPF was immunosuppression with a variety of agents, with or without the addition of the oral antioxidant, NAC. In the late 2000s, most respiratory physicians used either PRED plus AZA with or without NAC for their patients,\(^{67}\) in keeping with consensus guidelines at the time.\(^{68}\) The data supporting triple therapy (PRED/AZA/NAC) was obtained from a study examining PRED/AZA versus PRED/AZA/NAC, suggesting the addition of NAC improved outcomes.\(^{22}\) The use of PRED/AZA in IPF was based on a single study in the early 1990s using small numbers (27 patients) with no statistically significant outcomes,\(^{69}\) and whilst there had been observational studies regarding PRED in pulmonary fibrosis in the early 1980s,\(^{70}\) there had never been a randomized trial examining the use of PRED alone.

In order to address these knowledge gaps, the PANTHER IPF trial was established examining the effect of NAC alone (plus matched placebos for AZA and PRED), PRED/AZA/NAC triple therapy and triple placebo.\(^{20}\) The study was stopped early as the death rate in the triple therapy arm was 10% versus 1% in the triple placebo group, with a concomitant increased rate of hospitalization and AE. As such, triple therapy of IPF halted worldwide. The question of whether NAC alone was beneficial in IPF was addressed by a later publication that showed no benefit of NAC versus placebo in any outcome measure.\(^{21}\)

In Europe, oral NAC has been used in combination with pirfenidone, despite an absence of data. This approach has now been assessed in a randomized clinical trial, which has demonstrated that the addition of NAC therapy increases the risk of photosensitivity, and an exploratory analysis of change in FVC suggests that NAC plus pirfenidone may worsen lung function decline.\(^{22}\) As such, the use of pirfenidone with oral NAC cannot be recommended.
Summary

- Consistent with the international guidelines, the combination of PRED, AZA and NAC should not be used in the treatment of IPF.
- The current evidence does not support the use of NAC alone or in combination with pirfenidone for the treatment of IPF.

Anti-coagulation: warfarin

In IPF, a systemic procoagulant state is present, with an increase in both circulating factor VIII and platelet activation. An initial small and poorly controlled clinical trial of warfarin in IPF demonstrated a survival benefit\(^{29}\); however, a larger, definitive study (ACE-IPF) was stopped early due to an increased risk of death in the warfarin group.\(^{29}\) The increased mortality was not due to excess bleeding, but rather from disease progression, suggesting that warfarin worsens the fibrotic process.

Following this study, primary treatment of IPF using warfarin was abandoned, but the question remained, what should be done in patients who need anticoagulation for other clinical indications? This has been controversial, but there is growing evidence, although often retrospective and uncontrolled, that patients with confirmed IPF who are anticoagulated with warfarin for appropriate indications have an increased mortality.\(^{72,73}\) The most recent data,\(^{74}\) using a post hoc analysis of patients in the placebo arms of IPF trials analysed by warfarin use, has demonstrated a significant increase in mortality, with a hazard ratio of nearly five. At present, it is unclear if this risk is related only to warfarin or if it also applies to direct oral anticoagulants.

Summary

- Current evidence does not support the use of anticoagulation for the treatment of IPF.
- For patients on anticoagulation for other indications, careful consultation with appropriate specialists regarding the indications, risks and benefits of anticoagulation is suggested before any alterations are made.

Anti-reflux therapy

Patients with IPF have a high prevalence of gastro-oesophageal reflux disease (GORD), although the reported prevalence varies widely depending at least in part on how GORD is ascertained.\(^{76,77}\) and in half it is asymptomatic. Patients with IPF are also more likely to have a hiatus hernia.\(^{78}\) This strong and long-recognized association suggests either that GORD contributes to IPF pathogenesis (for instance through microaspiration with subsequent alveolar epithelial injury), and/or that IPF predisposes to GORD (for instance via changes in intrathoracic pressures during respiration) or that the two diseases share a common cause, and has further led to the idea that antacid therapy or even surgical fundoplication may be an effective therapeutic strategy for IPF.

Unfortunately, there are no randomized-controlled studies to address this hypothesis; however, in 2006, two relatively small retrospective studies were published suggesting a possible therapeutic benefit of antacid therapy\(^{79}\) and surgery,\(^{80}\) leading the ATS/ERS to cautiously recommend treatment of asymptomatic gastro-oesophageal reflux in the 2011 guidelines.\(^{1}\) A more recent, larger, but again post hoc analysis of the patients enrolled in the placebo arms of the three IPFnet randomized trials provided further support for this position\(^{81}\) leading the ATS/ERS in the 2015 guideline update to again cautiously suggest that antacid treatment should be prescribed for patients with IPF;\(^{4}\) although the confidence of this recommendation was low. Most recently, two large post hoc analyses of the pooled data from the pirfenidone\(^{82}\) and nintedanib\(^{83}\) studies found no benefit of antacid therapy. Concerningly, in the pirfenidone studies, use of antacid therapy was associated with an increased risk of generalized and respiratory infections in patients with more severe (FVC < 70%) IPF.\(^{84}\) There are no suitably controlled data to define the effect of fundoplication on the natural history of IPF, but an NHLBI (National Heart, Lung, and Blood Institute)-sponsored randomized controlled trial of laparoscopic fundoplication in IPF (NCT01982968) is ongoing and is expected to report results in 2017.

Summary

- There is conflicting evidence regarding the role of antacid therapy in IPF. Only observational data exist, with some studies suggesting benefit, some suggesting no benefit and one suggesting potential for harm. Since appropriately designed studies assessing the roles of medical or surgical treatment of gastro-oesophageal reflux in IPF are awaited, it remains unclear whether these treatment strategies confer benefit.

Current and future trials

While the discovery of anti-fibrotic therapy has been the recent focus of IPF management, it is important to highlight that there has also been significant progress in the understanding of IPF pathobiology. Preclinical trials have resulted in the discovery of several pathways thought to contribute to inflammation and fibrosis in IPF and are now the subject of targeted therapy. Despite recent advances in IPF treatment, anti-fibrotic medications only decrease the disease progression by approximately 50% at 12 months, still leaving a large unmet clinical need for further therapies. Table 2 describes a comprehensive list of novel therapies currently undergoing study from clinical trials database including NIH (National Institutes of Health)\(^{85}\) and European Union clinical trials register and ‘IPF watch’. These trials are at various stages of recruitment and completion.

In addition to pharmacological interventions, cell therapy is at an early stage of development. A seminal phase 1 study establishing the safety of mesenchymal stromal cell infusion in IPF\(^{86}\) has been completed. There are further studies underway and the ‘Study of Autologous Mesenchymal Stem Cells to Treat IPF’ (NCT01919827) is a phase 1, open, multicentre, non-
randomized, study with escalating doses, which will evaluate the safety and efficacy of mesenchymal stem cells in IPF.

**Treatment of AE**

AE-IPF has been defined by an international task force as an acute, clinically significant respiratory deterioration characterized by evidence of new, widespread alveolar abnormality, in a patient with a previous or concurrent diagnosis of IPF, where the deterioration is not fully explained by cardiac failure or fluid overload. This definition has recently been modified to include exacerbations with a known cause (e.g. infection), as well as those of unknown aetiology. The rationale behind this change is that although the aetiology of AE-IPF remains uncertain, it appears likely that many exacerbations may be triggered by an external insult such as infection or microaspiration, and there are little data to suggest that there is a meaningful distinction between these two. Identification of a cause for an AE-IPF does not appear to alter prognosis, although this is an area of ongoing research interest.

AE-IPF are more common in patients with physiologically advanced lung disease, with low FVC being the most consistent risk factor; other physiological parameters have also been associated with increased risk, including low DLCO and reduced 6-min walk distance (6MWD).

The prognosis of AE-IPF is poor. The median survival of patients who have AE-IPF is approximately 3–4 months, and up to 46% of deaths in IPF are preceded by an AE. Respiratory failure from AE-IPF is associated with high in-hospital mortality (>50% in most series). There remain no proven effective therapies for AE-IPF. Management includes supportive care including supplemental oxygen to correct hypoxaemia, palliative care, as well as those of unknown aetiology. The decision to undertake mechanical ventilation in this setting needs to be carefully considered, as the in-hospital mortality is as high as 90% in this population. In individual situations (e.g. following identification of a specific treatable cause for the exacerbation such as infection or pulmonary embolism, or as a bridge to lung transplant), such a decision may be considered appropriate. The ATS/ERS guidelines recommend against mechanical ventilation, stating that ‘the majority of patients with respiratory failure due to IPF should not receive mechanical ventilation, but mechanical ventilation may be a reasonable intervention in a minority’ (weak recommendation, low-quality evidence).

Corticosteroids are often used in AE-IPF, although there is no controlled evidence to support this. Although there are only anecdotal reports of benefit, in the absence of other therapies, and in view of the poor prognosis of AE-IPF, corticosteroids are often given in this situation. The ATS/ERS guidelines include a weak recommendation that the majority of patients with AE-IPF should be treated with corticosteroids. Other treatments may be considered for AE-IPF. Observational cohort studies of a number of therapies (cyclophosphamide, cyclosporine, rituximab combined with plasma exchange and intravenous (i.v.) immunoglobulin, tacrolimus, i.v. thrombomodulin, polymyxin-B-immobilized fibre column haemoperfusion) have suggested benefit; however, there are no randomized controlled trials and the routine use of these agents outside a clinical trial setting is not supported by the current evidence.

In the absence of effective treatment for AE-IPF, prevention of such events becomes important. There are some data to support the use of nintedanib to prevent the development of AE-IPF. Additionally, a cohort study using subjects from placebo arms of clinical trials showed a reduction in AE in those on anti-acid therapy. Further studies are required before recommendations can be made for prevention of AE-IPF.

**Summary**

- The prognosis of AE-IPF is poor. Available treatment options are limited, and not supported by controlled trial data. Further studies of prevention and treatment strategies for AE-IPF are needed.

**Treatment of co-morbidities**

Optimization of co-morbidities in IPF patients can enhance quality of life and in some patients longevity. Early recognition and treatment of infections, regular vaccinations and routine health screening are also important preventative strategies in this population. Prevalent co-morbid diseases in IPF patients include cardiovascular disease, GORD, pulmonary embolism, lung cancer, pulmonary hypertension (PH), emphysema/airway disease and obstructive sleep apnoea (OSA). Whilst there is limited specific evidence for treatment of these conditions in IPF patients, targeted therapy may be considered where benefits are likely to outweigh potential harm.

**Pulmonary hypertension**

PH is reported to occur in 3–86% of IPF patients, resulting in poorer survival. Variations in the severity of fibrotic lung disease across study populations, as well as differences in PH diagnostic methodology account for this wide range, and thus the true prevalence is uncertain. Most IPF patients with PH will have only mild or moderate severity pulmonary vascular disease; however, a subset of approximately 10% will develop severe PH, with associated right heart failure.

The majority of patients fall within Group 3 of the classification scheme set out by the European Society of Cardiology/European Respiratory Society (ESC/ERS), that is ‘PH associated with lung diseases and/or hypoxia’, although some patients may also have elevated pulmonary pressures from concomitant left heart disease (Group 2 PH). There are currently no specific vasodilator therapies indicated for Group 3 PH. Trials in sildenafil, bosentan, ambrisentan and macitentan have been disappointing, with all failing to demonstrate efficacy in the IPF population (Table 1). A recent placebo-controlled trial using riociguat in the
### Table 2  Current trials for the treatment of idiopathic pulmonary fibrosis

| Study | Intervention | Mode of action | Phase | Primary outcome | Company/ countries |
|-------|--------------|----------------|-------|-----------------|-------------------|
| NCT01766817 | BMS-986020 | Lysophosphatidic acid (LPA) antagonist | 2 | Safety and efficacy | Bristol Myers Squib, NY, USA |
| NCT02257177 | TD 139 | Galactin-3 inhibitor | 2 | Safety and tolerability | Galecto Bitotec, Scotland |
| NCT02688647 | KD025 | ROCK2 inhibitor | 2 | Safety, tolerability and activity | Kadmon Corporation, NY, USA |
| NCT02036580 | Tralokinumab | IL-13 blocker | 2 | Safety, tolerability and dose finding | AstraZeneca, Japan |
| NCT02874989 | Dasatinib + Quercetin | Tyrosine kinase inhibitor + anti-inflammatory | 1 | Safety | Wake Forest School of Medicine |
| NCT02315586 | Apolipoprotein A1 mimetics | Anti-inflammatory | 1 | Safety |  |
| NCT02397005 | ZL2102 | Anti-inflammatory | 1 | Safety | Perth |
| NCT02173145 | Azithromycin | Immunomodulation/anti-inflammatory | 2 | Efficacy against cough | Berne |
| NCT00262405 | Zileuton | Anti-inflammatory | 2 | Compared with azathioprine/ prednisolone | University of Michigan |
| NCT00786201 | CNTO 888 Carlumab | Immunomodulation | 2 | Evaluate the safety and effectiveness | Centocor Inc, PA, USA |
| NCT02345070 | SAR156597 | Immunomodulation | 2 | Safety and efficacy | Sanofi, France |
| NCT02085018 | Omeprazole | Attenuate acid reflux | 2 | Efficacy | Newcastle-upon-Tyne hospitals |
| NCT02759120 | Doxycycline or co-trimoxazole | Immunomodulation | 3 | Efficacy | Weill-Cornell |
| EUDRACT 2014-004058-32 | Co-trimoxazole | Immunomodulation | 2 | Efficacy | Norfolk and Norwich University |
| NCT01890265 | FG-3019 | Antibody against CTGF | 2 | Safety and efficacy | Fibrogen, San Francisco, CA, USA |
| NCT00463983 | SOM230 | Octreotide | 1 | Safety | France |
| NCT00189176 | Tetramethylxylene | Copper chelator reduces collagen-1 | 2 | Safety and efficacy in patients who failed previous treatment | University of Michigan |
| NCT01872689 | Lebrikizumab | Inhibits (IL-13), peristin | 2 | Safety and efficacy | Hoffman La Roche |
| NCT02648048 | Vismodegib | Antagonist of hedgehog signalling | P1b | Safety and tolerability in combination with pirfenidone | Hoffman La Roche, Switzerland |
| NCT01619085 | BIBF 1120 | Tyrosine kinase inhibitor | 2 | Long-term safety | Boehringer Ingelheim, Germany |
| NCT02538536 | PBI-4050 | Reduces TGF, CTGF | Safety and tolerability | Prometic Biosciences, Isle of Man |
| NCT01462006 | Sirolimus | mTOR inhibitor | 2 | Test if drug reduces circulating fibrocytes | University of Virginia |
| NCT02738801 | GLPG1690 | Autotaxin inhibitor | 2 | Exploratory phase 2a study | Galapagos |
idiopathic interstitial pneumonias, including IPF (the RISE-IIP study), was discontinued prematurely due to an increased risk of death and serious adverse events in the treatment arm.

The STEP-IPF trial using sildenafil versus placebo in patients with advanced IPF (but not necessarily with PH) provides some indirect support for vasodilator therapy in selected patients. Whilst the primary outcome measure of ≥20% improvement in 6MWD was not met, secondary outcomes of gas transfer, oxygenation, breathlessness and quality of life were significantly improved with the intervention.93 Patients with suspected moderate-to-severe PH may be referred to specialist centres for consideration of right heart catheterization and a trial of sildenafil, with ongoing close surveillance.100 Supplemental oxygen and diuretics may also improve symptom burden and haemodynamics in severe patients with associated right heart failure.

**Summary**
- All trials of specific vasodilator therapy for PH in IPF have been negative in terms of their primary end point.

**Sleep-disordered breathing**
Sleep-disordered breathing (SDB) is reportedly common in IPF cohorts, with observed frequency ranging between 59% and 90%.93,101–103 Nocturnal hypoxaemia is also prevalent, occurring both with and without associated apnoeas, due to ventilation/perfusion inequality, alveolar hypoventilation and their position on the steep portion of the oxy-haemoglobin dissociation curve. Two studies have linked increased mortality risk with the number of nocturnal desaturation events and nadir sleep oxygen saturation in ILD patients.103,104 Justifications for investigation and treatment of SDB in this population include the association between OSA and nocturnal hypoxaemia; however, the optimal timing of these investigations is unclear.

A non-randomized study of IPF patients with moderate-to-severe OSA suggested improved daytime functioning and sleep quality at 12 months along with improved survival at 2 years, in those compliant with continuous positive airway pressure (CPAP) versus those who were non-compliant.111 Although potentially subject to confounding bias, this study provides supportive evidence for a proactive approach to SDB in this patient group. Thus, when moderate-to-severe OSA is identified in IPF patients, a trial of CPAP therapy may be appropriate. Specialist sleep clinic input is recommended, given the difficulties that many fibrotic lung disease patients have with tolerating positive pressure ventilation during sleep. Supplemental nocturnal oxygen therapy is recommended for IPF patients with significant nocturnal hypoxaemia (as described in further detail in *Non-pharmacological therapy: Oxygen*). This may also be a reasonable strategy for patients poorly tolerant of CPAP; however, there is limited published evidence to support this.

**Summary**
- OSA and nocturnal hypoxia occur frequently in IPF patients.
- Sleep studies could be considered when sleep apnoea or nocturnal hypoxia is suspected.

**Combined pulmonary fibrosis and emphysema**
Combined pulmonary fibrosis and emphysema (CPFE) is a recently defined syndrome describing the coexistence of pulmonary fibrosis and radiological emphysema in individuals with significant tobacco exposure.112 It is
presently unclear whether this entity represents a distinct disease phenotype or is simply the coincidence of two processes with a common aetiology. The majority of patients with CPFE have the UIP pattern of IPF on HRCT, although other ILD patterns can be seen, including desquamative interstitial pneumonia. Patients with CPFE typically have preserved spirometry and lung volumes despite extensive disease. Airflow obstruction is present in some, but not all CPFE patients. Both DL_{CO} and K_{CO} (transfer co-efficient of the lung (i.e. DL_{CO}/VA)) are usually severely reduced. Profound oxygen desaturation is common and the majority will progress to develop resting hypoxaemia. PH is present in up to 50% of CPFE patients at diagnosis, with an associated increased mortality risk beyond that of CPFE patients without PH and of IPF patients without emphysema. The risk of lung cancer is also higher for CPFE than for either IPF or chronic obstructive pulmonary disease (COPD) alone.

Therapeutic options for CPFE are currently very limited, with a paucity of clinical trials in this disease subset. Patients with emphysema greater than the extent of pulmonary fibrosis were specifically excluded from the trials of pirfenidone and nintedanib. Patients who had emphysema extent less than fibrosis on HRCT with a forced expiratory volume in 1 s (FEV1)/FVC ratio of >80% were, however, included in the ASCEND and INPLUSIS studies, suggesting that the presence of emphysema may not necessarily preclude response to treatment. A post hoc analysis from the INPULSIS studies of patients with emphysema on HRCT compared with those without emphysema demonstrated similar efficacy for nintedanib in patients with CPFE.

Vasodilator agents have not been trialled in CPFE patients with associated PH. Such therapies should be administered with caution, given the potential for worsening hypoxaemia due to increased ventilation/perfusion mismatch. As with IPF-related PH, CPFE-PH requires specialist centre management. Standard bronchodilator therapy may benefit those with airflow limitation. Supplemental oxygen is suggested for patients with PH and developing right heart failure. CPFE patients should be referred to either lung transplantation or palliative care services where appropriate.

**Summary**

- **There is increased risk of both PH and lung malignancy in patients with CPFE.**
- **Supplemental oxygen and inhaled bronchodilator therapy may help relieve breathlessness in some patients with CPFE.**
- **In a subset of patients with fibrosis greater than emphysema and FEV1/FVC > 80%, there is evidence to suggest a benefit from anti-fibrotic therapy.**

**NON-PHARMACOLOGICAL THERAPY**

**Oxygen**

Adverse outcomes are predicted by resting oxygen requirements as well as degree of exercise- and sleep-related hypoxaemia in IPF. At the present time, it is unknown whether prevention of hypoxaemia with supplemental oxygen under these circumstances assuages the increased mortality risk. Surprisingly, there are very few studies investigating the use of oxygen in IPF populations.

**Oxygen prescribing guidelines**

Current recommendations for supplemental oxygen in IPF and other ILD patients are extrapolated from two landmark trials in COPD. Australian/NZ guidelines advise oxygen therapy for patients with chronic lung disease who have resting hypoxaemia (PaO2 (arterial oxygen partial pressure) < 55 or < 60 mm Hg in the presence of hypoxic organ damage (including poly-cythaemia, PH or right heart failure)). Intermittent ambulatory oxygen may be considered for those with exercise-induced desaturation where an improvement is seen in exercise capacity or dyspnoea, as assessed with a blinded trial of oxygen versus air during the 6-min walk test (6MWT). Guidelines also recommend nocturnal oxygen for respiratory patients who desaturate below 88% for at least one-third of total sleep time, in the absence of concomitant SDB. With largely equivocal evidence, an individualized approach for the latter two indications is advised.

**Ambulatory oxygen during exercise**

In many countries, oxygen is routinely provided during exercise training in ILD patients who are known to desaturate. Two small IPF study cohorts demonstrated improved endurance and maximal work rate whilst breathing FiO2 (fraction of inspired oxygen) (60% versus 21%) during incremental cardiopulmonary exercise testing. Ambulatory oxygen during 6MWT was seen to improve walk distance, heart rate, SpO2 (oxygen saturation) recovery and subjective dyspnoea scores in two retrospective studies of IPF subjects. The improvement in walk distance remained significant in the subgroup that carried their portable cylinders during the test, reflective of an encumbrance that could potentially limit the benefits of ambulatory oxygen in everyday practice. However, in a more recent prospective trial, IPF patients did not improve their 6MWD using 4 L/min of oxygen compared with air. To date, there have been no published studies examining the longer term benefits of ambulatory oxygen for those who desaturate with exercise but are not hypoxic at rest. There are also no data on its impact on quality of life; however, a large randomized control trial addressing this question is currently underway (AmbOx study, NCT02286063).

**Nocturnal oxygen**

Guidelines advocate supplemental nocturnal oxygen for chronic lung disease patients with significant sleep desaturation, albeit with minimal supportive data. In the COPD literature, overnight oxygen therapy has not been demonstrated to improve survival in those patients with nocturnal hypoxia but daytime normoxia. Pulmonary haemodynamics may be improved in COPD patients receiving long-term nocturnal oxygen; however, this has not been investigated in IPF populations. In two single-night studies in ILD
subjects, oxygen reduced breathing frequency and heart rate through elimination of sleep-associated desaturation; however, sleep quality and arousal index were not significantly altered.\textsuperscript{135,136} 

**Continuous oxygen therapy**
The literature is equally sparse in the application of oxygen for IPF patients who are hypoxaemic at rest. A Cochrane review, updated in 2010, included only one unpublished reference.\textsuperscript{137} This trial randomized 62 ILD patients to receive either LTOT or no oxygen (Braghiroli A, Donner CF, personal communication with permission). Mortality at 12, 24 and 36 months was the same in each group. Physiological and quality of life data were not reported. With ethical considerations of allocating placebo to hypoxaemic subjects, it is unlikely that such a study will be repeated. IPF-specific guidelines make a strong recommendation for LTOT in those with resting hypoxaemia, but acknowledge the lack of evidence specific to this disease group.\textsuperscript{1,124,125} 

**General considerations and summary**
There are many practical issues to take into account when prescribing oxygen, particularly in the ambulatory setting. Important factors include the cost of portable concentrators, the physical challenges of carrying or pulling a delivery device and the limited duration of cylinder oxygen delivery and need for frequent refills. It is currently not known whether continuous versus pulse flow delivery meet patient needs equally, particularly in advancing disease. Local oxygen funding bodies vary in their equipment provision for those who fulfil criteria, and this will also influence choice of delivery modality. 

**Summary**
- Consistent with international guidelines, clinicians should offer LTOT for IPF patients with resting hypoxaemia, and consider supplemental oxygen for those with significant exercise- and sleep-related oxygen desaturation.

**Pulmonary rehabilitation**
It is common for patients with IPF to experience dyspnoea on exertion, poor health-related quality of life and marked exercise intolerance. These impacts persist in patients using anti-fibrotic therapies\textsuperscript{12,13} and often worsen as the disease progresses. There is growing evidence that pulmonary rehabilitation has important effects on symptoms, functional capacity and well-being in patients with IPF. A Cochrane review examining randomized controlled trials of pulmonary rehabilitation in ILD\textsuperscript{138} reported that in the subgroup with IPF, 8–12 weeks of supervised pulmonary rehabilitation produced improvements in 6MWD that exceed the minimal important difference (mean: 36, 95% CI: 16–55 m). There were also significant improvements in dyspnoea and health-related quality of life with moderate effect sizes. All pulmonary rehabilitation programmes included whole-body endurance training (walking or cycling), most included resistance (strength) training and some also included education, nutrition counselling and psychosocial support. 

The ATS/ERS guideline for IPF management makes a weak recommendation in favour of pulmonary rehabilitation for IPF, which indicates that pulmonary rehabilitation should be used in the majority of patients.\textsuperscript{1} This recommendation recognizes the uncertainty regarding the duration of benefit; the only trials that have examined long-term outcomes have reported that gains in exercise capacity diminish in the 6–12 months following pulmonary rehabilitation, although health-related quality of life may be better preserved.\textsuperscript{139,140} Early referral to pulmonary rehabilitation should be considered as patients with milder disease appear to have more sustained benefit.\textsuperscript{141} The ATS/ERS pulmonary rehabilitation statement\textsuperscript{142} also reports that pulmonary rehabilitation delivers meaningful short-term benefits in patients with IPF, whilst acknowledging the challenges in providing rehabilitation for patients who may have progressive disease. Recently, the Australian and New Zealand Pulmonary Rehabilitation Guidelines have made a weak recommendation for pulmonary rehabilitation in patients with ILD, including those with IPF.\textsuperscript{143} The guideline authors found no evidence that exercise prescription should differ from the standard protocols that have been used for many years in patients with COPD, suggesting that patients with IPF can be successfully treated in existing pulmonary rehabilitation services.

In Australia and NZ, most pulmonary rehabilitation programmes will accept referrals for patients with IPF. However, those with IPF experience similar barriers to pulmonary rehabilitation attendance as others with chronic lung disease, including fear of exercise and associated breathlessness, the burden of regular travel to attend the programme and a lack of perceived benefit. These barriers should be explicitly addressed at the time of referral, preferably by the treating medical team, as encouragement from the doctor is a key facilitator of pulmonary rehabilitation uptake.\textsuperscript{144} Because patients with IPF frequently use supplemental oxygen or experienced marked exercise-induced desaturation, it is preferable for pulmonary rehabilitation to take place in programmes that have the capacity to deliver oxygen during training, consistent with exercise training protocols for patients with IPF of known effectiveness.\textsuperscript{138} Although the educational curriculum for pulmonary rehabilitation was originally designed for COPD, patients with IPF would prefer that disease-specific information was delivered during the programme, including management of cough, how to handle IPF medications and their side effects and optimal disease management for IPF.\textsuperscript{145} 

**Summary**
- Pulmonary rehabilitation confers meaningful benefits in exercise capacity, symptoms and health-related quality of life, especially in patients with milder disease.
- Patients with IPF can be successfully managed in existing pulmonary rehabilitation programmes and early referral to pulmonary rehabilitation is encouraged.
Lung transplant
Despite the recent advances in IPF therapy, there is still no cure for this relentlessly progressive disease. As a result, lung transplantation remains the only definitive treatment for selected patients with IPF.

The timing of referral for lung transplantation consideration is important and should be early in the course of the disease. Patients can wait a long period of time for suitable lungs, as the small chest cavity can limit the suitability of donor organs and thus prolong wait times. A recent consensus document for the selection of lung transplant candidates recommends referral of appropriate candidates with a diagnosis of IPF at the time the diagnosis is made, regardless of the severity of their disease at lung function testing. This recommendation reflects the phenotypic heterogeneity of IPF, the difficulty in predicting disease course and overall poor prognosis of IPF patients compared with other indications for lung transplantation.

The heterogeneity of IPF is illustrated by the fact that although the median wait list time to transplant is lower in IPF than in other diagnoses, the mortality on the waiting list is higher. A recent paper from a single centre in Italy also shows that the diagnosis of IPF was associated with the highest mortality on the lung transplant waiting list. Factors associated with greater mortality include higher levels of CO₂ and the need for higher flows of O₂.

Indications for listing for lung transplantation include: a decrease in FVC ≥ 10% or DLCO ≥ 15% over 6 months, desaturation to ≤88% on 6MWT, a decrease in 6MWD during follow-up, PH as well as hospitalization for respiratory decline, pneumothorax or AE. The absolute and relative contraindications for lung transplantation are outlined in Table 3. Of note, age >65 years is no longer an absolute contraindication to lung transplantation. Rather than chronological age alone, the physiological reserve of the patient as assessed by a variety of frailty measures and the presence of co-morbidities with end organ damage are important contributing factors to the decision for lung transplant listing.

Outcomes after lung transplantation are less than ideal, with a median survival post lung transplantation for IPF of 4.5 years. This is well below that of lung transplantation for cystic fibrosis and COPD (7.8 and 5.4 years, respectively). The reasons for this discrepancy are not clear, but include the age of the recipients and the presence of co-morbidities. This does not however explain all of the variances. However, recent attempts to further define the risks of early mortality post lung transplantation have not found IPF to be an independent risk factor.

Unlike suppurative lung diseases, IPF patients are eligible for single, as well as double lung transplants. The choice is dependent on a number of factors including:
1. The availability of suitable donor lungs: Two recipients can be transplanted from the same donor. This is particularly relevant for smaller, blood group O potential recipients.
2. The size of the chest cavity: It is possible to transplant a larger single lung as the mediastinum will move over to accommodate the lung. This is particularly important in small potential recipients as the disease inherently further reduces the size of the chest cavity.

Reported outcomes comparing single versus double lung in IPF are conflicting with previous data suggesting no difference, with one recent publication reporting better outcomes for double lungs.

Summary
- Lung transplantation is a viable option for selected patients with IPF and confers a survival benefit.
- Consistent with the international lung transplantation consensus document, early referral to a transplant centre is essential, as it is difficult to accurately predict disease trajectory in IPF.

Palliative care
Despite advances in pharmacotherapy, dyspnoea, cough and fatigue remain debilitating symptoms and

Table 3 Contraindications to lung transplantation

| Absolute contraindications | Relative contraindications |
|----------------------------|---------------------------|
| Malignancy within the last 2–5 years | Age >65 with low physiological reserve |
| Other untreatable major organ dysfunction | Mechanical ventilation and/or extracorporeal life support |
| Uncorrectable atherosclerotic disease with end organ dysfunction | Progressive or severe malnutrition |
| Acute medical instability or bleeding diathesis | Severe, symptomatic osteoporosis |
| Chronic infection with highly virulent and/or resistant microbes including active *Mycobacterium tuberculosis* infection | Colonization or infection with highly resistant or virulent microbes |
| BMI > 35.0 kg/m² | BMI > 30 kg/m² |
| Non-adherence to medical therapy | Extensive prior chest surgery with lung resection |
| Psychiatric or psychological conditions associated with inability to cooperate with healthcare team | Hepatitis B and/or C |
| Absence of social support system | HIV infection |
| Severely limited functional status with poor rehabilitation potential | Suboptimal treatment of diseases with potential for end organ damage |
| Substance abuse/dependence | |

---

*Respirology* (2017) 22, 1436–1458 © 2017 The Authors

Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology
are often difficult to manage. It is important to recognize that these symptoms can affect patient’s quality of life and sense of well-being independent of physiological measures of disease. Palliative care focuses on symptom management, advance directives and end-of-life planning, aiming to improve the quality of life of patients and their families. Palliative care is an integrated and individualized process which should be addressed at all stages of disease and not exclusively at the end of life. It is a dynamic process where goals shift to meet the changing needs of patients.

There are emerging data on palliative treatments and their benefits in IPF, although approaches have often been extrapolated from studies of other chronic lung diseases. Management consists of both non-pharmacological (e.g. counselling and spiritual care support) and pharmacological approaches, and are often used in parallel. In addition to treatment for specific symptoms, effective management of psychological stress and pulmonary rehabilitation is vital, with beneficial effects across multiple domains. The use of oral opioids has been reported to reduce dyspnoea, whilst limited evidence exist for the use of benzodiazepine and supplemental oxygen. A thorough search for reversible causes of cough (including gastro-oesophageal reflux, postnasal drip, ACE inhibitor use etc.) is crucial before considering the use of opioids or over the counter cough suppressants, although there is little evidence that these measures are effective in IPF. Low-dose PRED may benefit some patients, although a risk/benefit assessment must be considered for each individual patient. Thalidomide has been reported to significantly reduce cough, however, it is not widely available and is associated with significant side effects.

Although confronting, IPF patients desire information about their prognosis and how IPF manifests in the end stages, many physicians fail to address this. This could be due to a number of reasons, including prognostic uncertainty of IPF, fear of diminishing hope, discomfort with palliative care discussions and limited understanding of potential benefits of palliative care. The main obstacle is likely to be fear of diminishing hope, although findings from studies of cancer and other terminal illnesses suggest that patients who were referred early to palliative care had a better quality of life, experienced less depressive symptoms and even had a longer survival. Advance care planning should be offered to patients when they are well and are able to discuss their wishes. Palliative care should be viewed as ‘supportive care’, and should be addressed early as pharmacotherapy in IPF remains largely ineffective for the control of symptoms.

Summary

- Dyspnoea, cough and fatigue are prominent and debilitating symptoms, independent of disease severity. To date, no therapeutic options in IPF have been shown to improve these symptoms. Early palliative/supportive care may be helpful to address this.
- Advance care planning, although daunting to patients, families and their doctors, can be offered when patients are relatively well, so that their wishes and those of their families can be heard and respected.

Psychosocial support

Living with IPF is challenging for patients and their families. Patients describe struggling to manage dyspnoea, cough and fatigue; a lack of good quality information about their condition and their treatment options; loss of independence and loss of previous life roles; and inadequate emotional support. Because IPF is poorly understood in the community, patients report difficulty in explaining their disease to family and friends. The most common unmet needs reported by patients across the world are for high-quality, honest and reliable disease information that is accessible from the time of diagnosis; emotional support to assist patients and their families to cope with the diagnosis and deal with the ongoing anxiety of living with a progressive disease; and patient-based advocacy groups who could effectively represent the needs of patients with IPF in the broader community.

There are a variety of models for patient and family support. A disease management programme for IPF was tested in a randomized controlled trial where 21 patient/carer dyads received either six once-weekly group sessions covering important aspects of IPF management including disease-specific education to patients and their families with IPF and their families with a range of resources for education, psychosocial support and advocacy. These include disease-specific educational materials; a peer support programme that connects patients living with IPF via telephone to share experiences, knowledge and support; regular scientific conferences that include a consumer stream to ensure that patients...
and their families can access the most up-to-date information on IPF care; and public advocacy for evidence-based care and research to improve IPF outcomes. Further information can be found on the Lung Foundation Australia website (www.lungfoundation.com.au). Unfortunately, no such resource is currently available for the NZ population specifically.

**PRECISION MEDICINE**

The heterogeneity of the natural history of IPF has led to a worldwide search for a panel of biomarkers enabling physicians to target treatment to the individual IPF patient. Investigators are searching for biomarkers which can aid in IPF diagnosis and in assessing prognosis. Most of this work is being conducted to identify circulating biomarkers in peripheral blood; however, biomarker discovery using lung biopsies is also underway. Some of the most promising early candidates are the matrix metalloproteinases (MMP, especially MMP-7), surfactant protein-D and endothelin-1.

IPF, including not only its rare familial forms but also its much more common sporadic form, is a disease associated with gene mutations. The genes most commonly mutated are the mucin 5B (MUC5B), surfactant protein and toll-interacting protein (TOLLIP), as well as those associated with maintenance of telomere length. Importantly, not only do mutations in these genes increase the risk of developing IPF, but some of them also provide important prognostic information. For instance, patients with MUC5B mutations appear to have better survival, whilst those with short telomere length have worse survival. In fact, assessing telomere length and identifying germline mutations in genes which assist in telomere maintenance in patients suspected of having a mutation are emerging as a part of the workup for patients presenting with fibrotic ILD (f-ILD) as these mutations lead to a variety of f-ILD but appear to universally confer a worse prognosis.

Although prospective studies are awaited, it is likely that determination of a patient’s genotype and their specific biomarker profile will become an essential part of clinical practice, for example to not only diagnose IPF, but also to assist the physician in deciding if and when to recommend commencement of anti-fibrotic therapy, and when to refer for transplantation. The strength of these associations mean that future large studies in IPF will likely stratify by genotype and/or biomarker profile, meaning that ultimately specific therapies will be found to be appropriate for a subpopulation of patients with IPF—allowing ‘precise’ use of powerful medicines.

This idea that treatments should be personalized to maximize efficacy and safety is of course not new, especially in oncology, but does imply a more in-depth understanding of disease pathogenesis. Examples of this kind of approach are already appearing for IPF—for example in a post hoc analysis, mutations in the TOLLIP gene predicted response to NAC in what was otherwise a negative trial when all patients were pooled. Naturally, prospective studies are required to confirm these potentially exciting observations.

Nevertheless, this accumulated experience and the strength and frequency of the genetic associations observed so far point to IPF, alongside cancer, being one of the first respiratory diseases to enter the ‘personalized’ or ‘precision’ medicine era.

**Summary**

- While biomarkers show early promise in identifying IPF, assessing prognosis and stratifying management, further studies are required before any clinical recommendations can be made.

**SPECIFIC APPLICATION TO AUSTRALIA AND NZ**

Regional factors specific to Australia and NZ influence the manner in which the above-described therapies are applied to their respective IPF populations. Within both countries, funding for anti-fibrotic therapy is dependent on the patient displaying features representing an amalgamation of the inclusion criteria of the phase 3 studies of nintedanib and pirfenidone.

In Australia, the PBS (pharmaceutical benefits scheme) has approved funding for both pirfenidone and nintedanib. Specific features of Australia’s prescribing criteria include the need for diagnosis to be confirmed by a multidisciplinary team and the presence of a mild to moderate restrictive pattern on lung function testing (Table 4). In NZ, PHARMAC has approved funding of pirfenidone only, but has restricted prescription to patients with moderate disease, providing there is no disease progression (defined as a decline in percent predicted FVC of 10% or more) within any 12-month period while on therapy (Table 4). The differences in the funding criteria between Australia and NZ likely reflect differences in the interpretation of the evidence for these medications. As clinical trials in pirfenidone, the only antifibrotic medication approved in NZ, restricted patients to those with moderate disease (FVC: 50-80%), this is reflected in the NZ prescribing guidelines.

These restrictions to supply anti-fibrotic medications for subjects for whom there is clear evidence of efficacy is understandable in the context of the burden of such therapies on health budgets. Equally important though is the reconsideration of such restrictions as further data are published on the use of anti-fibrotic therapy, given the evolving nature of this relatively new therapeutic field. For example, there is gathering evidence to suggest that mandating the cessation of anti-fibrotics based on crossing thresholds of FVC percentage decline may be questionable. Analysis of the pooled ASCEND and CAPACITY data has demonstrated that, after a decline in FVC by ≥10% in the initial 6 months of therapy, continued therapy reduced the likelihood of further such decline or death over the subsequent 6 months compared with the placebo group. As the evidence for these medications continues to grow, physicians as well as patients must advocate for evolution of funding restrictions.

For the non-pharmaceutical therapies, each country has unique regulations for practice. In Australia, oxygen therapy may be funded by either federal or state
governments and differences exist between jurisdictions with regards to funding criteria, particularly for ambulatory therapy, where a relative absence of evidence exists to confirm its utility. While the limited nature of the availability of donor organs leads to a waiting list for lung transplantation, access is dependent on meeting those criteria outlined in Table 3, and no regional differences exist based on other patient features, such as duration of listing. While pulmonary rehabilitation, advanced care planning and palliative care services are readily available in many regional centres, providing community services in remote and rural locations is challenging.

In NZ, funding for oxygen and other support services, such as pulmonary rehabilitation, is provided by the district health boards as part of a capitated funding system. Lung transplantation is provided by a single centre and criteria for listing are similar to Australia. Rurality impacts access to services for patients with pulmonary fibrosis in both countries, but telemedicine and shared care allow improved access to MDM discussion and a variety of supports.

CONCLUDING STATEMENT

It is an exciting time for IPF management with new therapies shown to decrease disease progression now available. However, enthusiasm to prescribe these medications has to be tempered by the lack of evidence in many subgroups, as well as local restrictions for government funding of these therapies. The management of IPF patients is not constrained to anti-fibrotic therapies, and it is important to address co-morbidities and manage symptoms using pharmacological and non-pharmacological therapies. Despite new treatments, IPF remains a progressive and fatal disease and thus pulmonary rehabilitation, consideration of lung transplantation, palliative care and end-of-life planning are essential to the holistic care of IPF patients.

Disclosure statement

The authors’ disclosure statement is provided in Appendix S1 (Supplementary Information).

REFERENCES

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA et al.; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183: 786–824.
2. Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur. Respir. Rev. 2012; 21: 355–61.
3. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011; 183: 431–40.
4. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S et al.; American Thoracic Society; European Respiratory Society; Japanese Respiratory Society; Latin American Thoracic Association. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am. J. Respir. Crit. Care Med. 2015; 192: e3–19.
5. Jo HE, Randhawa S, Corte TJ, Moodley Y. Idiopathic pulmonary fibrosis and the elderly: diagnosis and management considerations. Drugs Aging 2016; 33: 321–34.
6. De Vries J, Kessels BL, Drent M. Quality of life in idiopathic pulmonary fibrosis patients. Eur. Respir. J. 2001; 17: 954–61.
7. Byrson CJ, Berkeley J, Carrieri-Kohlman VL, Pantiltz SZ, Landefeld CS, Collard HR. Depression and functional status are strongly associated with dyspnea in interstitial lung disease. Chest 2011; 139: 609–16.
8. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2005; 171: 1040–7.
9. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A et al.; Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary fibrosis. Eur. Respir. J. 2010; 35: 821–9.
10. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760–9.
11. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2011; 365: 1079–87.
12. Richeldi L, de Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cortin V, Flaherty KR, Hansell DM, Inoue Y et al.; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2671–82.
Treatment of IPF

13 King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L et al.; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2083-92.

14 King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stahler G, Leconte I, Roux S, Raghu G. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2008; 177: 75-81.

15 Idiopathic Pulmonary Fibrosis Clinical Research Network, Zuzanov DA, Schwartz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N. Engl. J. Med. 2010; 363: 620-8.

16 King TE Jr, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Nathan SD, Wells AU, Collard HR et al.; ARTEMIS-IPF Investigators*. Treatment of idiopathic pulmonary fibrosis with ambienctam: a parallel, randomized trial. Ann. Intern. Med. 2013; 158: 641-9.

17 Raghu G, Million-Rousseau R, Morganti A, Perchenet L, Behr J. MUSIC Study. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomized controlled MUSIC trial. Eur. Respir. J. 2013; 42: 1622-32.

18 Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen RN, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F et al.; IFGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005; 353: 2229-42.

19 Homma S, Azuma A, Taniguchi H, Ogura T, Mochiduki Y, Sugiyama Y, Nakata K, Yoshimura K, Takeuchi M, Kudoh S; Japan NAC Clinical Study Group. Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis. Respirology 2012; 17: 467-77.

20 Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2093-101.

21 Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE Jr; Idiopathic Pulmonary Fibrosis Study Group. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2004; 350: 125-33.

22 Raghu G, Brown KK, Costabel U, Cottin V, du Bois RM, Lasky JA, Thomeer M, Utz JP, Khandker RK, McDermott L et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 2008; 178: 948-55.

23 King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Swarzberg J, Thomeer M et al.; INSPIRE Study Group. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009; 374: 222-8.

24 Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR, Imatinib-IPF Study Investigators. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am. J. Respir. Crit. Care Med. 2010; 181: 604-10.

25 Pireddone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 2012; 366: 1968-77.

26 Behr J, Bendstrup E, Cestani B, Günther A, Olschewski H, Sköld CM, Wells A, Wuys W, Koschel D, Kreuter M, Wallaert B, Lin C-Y, Beck J, Albera C. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir. Med. 2016; 4: 445-53.

27 Behr J, Bendstrup E, Cestani B, Günther A, Olschewski H, Sköld CM, Wells A, Wuys W, Koschel D, Kreuter M, Wallaert B, Lin C-Y, Beck J, Albera C. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir. Med. 2016; 4: 445-53.

28 Horton MB, Santopietro V, Mathew L, Horton KM, Polito AJ, Liu MC, Danoff SK, Lechtzin N. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann. Intern. Med. 2012; 157: 398-406.

29 Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA. Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet). A placebo-controlled randomised trial of warfarin in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2012; 186: 88-95.

30 Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am. J. Respir. Crit. Care Med. 1999; 159: 1061-9.

31 Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur. Respir. J. 2016; 47: 243-53.

32 Lancaster L, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, King TE et al. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. BMJ Open Respir. 2016; 3: e000105.

33 Wollin L, Wex E, Pautsch A, Schnapp G, Hostetler KE, Stovasser S, Kolb M. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur. Respir. J. 2015; 45: 1434-45.

34 Hostetler KE, Zhong J, Papakonstantinou E, Karakulukis G, Tamm M, Seidel P, Sun Q, Mandal J, Lardinois D, Lambers C et al. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir. Res. 2014; 15: 157.

35 Costabel U, Inoue Y, Richeldi L, Collard HR, Tschoepe I, Stovasser S, Azuma A. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am. J. Respir. Crit. Care Med. 2016; 193: 178-85.

36 Raghu G, Wells AU, Nicholson AG, Richeldi L, Flaherty KR, Le Mauff F, Stovasser S, Schlenker-Herceg R, Hansell DM. Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria. Am. J. Respir. Crit. Care Med. 2017; 195: 78-85.

37 Koschel D, Cottin V, Skold M, Tommassetti S, Azuma A, Giot C, Yosum D, Haniza S, Mahan TF. Pirfenidone post-authorization safety registry (PASSPORT) - interim analysis of IPF treatment. Eur. Respir. J. 2014; 44: 1904.

38 Cestani B, Ogura T, Pelling K, Ceeck C, Quaresma M, Kreuter M, Kaye M. P7 interim analysis of nintedanib in an open-label extension of the INPULSIS® trials (INPULSIS®-ON). Thorax 2015: 70: A77-8.

39 Bonella F, Kreuter M, Hagnmeyer L, Neurohr C, Keller C, Kohlhauelf M, Müller-Quernheim J, Milger K, Prasse A. Insights from the German compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis. Respiratio 2016; 92: 98-106.

40 Wijsenbeek MS, Grutters JC, Wuys WA. Early experience of pirfenidone in daily clinical practice in Belgium and The Netherlands: a retrospective cohort analysis. Adv. Ther. 2015; 32: 691-704.

41 Harari S, Caminati A, Albera C, Vancheri C, Poletti V, Peschi A, Luppi F, Saltini C, Agostini C, Bargagli E et al. Efficacy of pirfenidone for idiopathic pulmonary fibrosis: an Italian real life study. Respir. Med. 2015; 109: 904-13.

42 Hughes G, Toellner H, Morris H, Leonard C, Chaudhuri N. Real world experiences: pirfenidone and nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis. J. Clin. Med. 2016; http://doi.org/10.3390/jcm5090078.

43 Ogura T, Taniguchi H, Azuma A, Inoue Y, Kondoh Y, Hasegawa Y, Bando M, Abe S, Mochizuki Y, Chida K et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur. Respir. J. 2015; 45: 1382-92.
4 Albera C, Costabel U, Fagan EA, Glassberg MK, Gorina E, Lancaster L, Lederer DJ, Nathan SD, Spirig D, Swigris JJ. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J. 2016; 48: 843-51.

46 Kolb M, Richeldi L, Behr J, Maher TM. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax 2017; 72: 340-6.

47 Arai T, Inoue Y, Sasaki Y, Tachibana K, Nakao K, Sugimoto C, Okuma T, Akira M, Kitaichi M, Hayashi S. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis. Respir. Investig. 2014; 52: 136-43.

51 Richeldi L, Azuma A, Selman M, Tang W, Capapie J, Stowasser S, Cottin V. Twenty-four week decline in forced vital capacity predicts mortality at week 52 in the INPULSiS® trials. Eur. Respir. J. 2016; 48: OA1814.

53 Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, Colby TV, du Bois RM, Hansell DM. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am. J. Respir. Crit. Care Med. 2003; 167: 962-9.

54 Kondoh S, Chiba H, Nishikiori H, Umeda Y, Kuronuma K, Okuma T, Akira M, Kitaichi M, Hayashi S. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis. Respir. Investig. 2014; 52: 136-43.
Treatment of IPF

1455

(2017)

90 Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T. Acute Collard HR, Ward AJ, Lanes S, Cortney Hay

91 Raghu G, Amatto VC, Behr J, Stowasser S. Comorbidities in idiopathic pulmonary fibrosis. 

92 Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Sugarbaker DJ, Bueno R. Laparoscopic fornalexpiration in patients with end-stage lung disease awaiting transplantation. Thorac. Cardiovasc. Surg. 2006; 131: 438–46.

93 Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, Yow E, Raghu G, IPNet Investigators. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir. Med. 2013; 1: 369–76.

94 Kreuter M, Wuys W, Renzoni E, Koschel D, Maher TM, Kolb M, Weycker D, Spagnolo P, Kirchgaesser K-U, Herrth FJP et al. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir. Med. 2016; 4: 381–9.

95 Collard HR, Corte TJ, Jenkins G, Kondob Y, Lederer DJ, Lee JS, Maher TM, Wells AU, Antoniou KM et al. Acute exacerbation of idiopathic pulmonary fibrosis. Interna
tional Working Group Report. Am. J. Respir. Crit. Care Med. 2016; 194: 265–75.

96 Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. 

97 Collard HR, Yow E, Richeldi L, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, Yow E, Raghu G, IPNet Investigators. Acute exacerbation of idiopathic pulmonary fibrosis: a case series. Respirology 2017; 22: 628–35.

98 Chambers DC, Enever D, Ilic N, Sparks L, Whitelaw K, Ayres J, Andreas S, Claussen M, Grohe C, Wilkens H. Sleep oxygen desaturation predicts survival in idiopathic pulmonary fibrosis. J. Clin. Sleep Med. 2013; 9: 593–601.

99 Corte TJ, Wright SJ, Talbot S, Macdonald PM, Hansen DL, Polkey M, Renzoni E, Maher TM, Nicholson AG, Wells AU. Elevated nocturnal desaturation index predicts mortality in interstitial lung disease. Sarcoideosis Vasc. Diffuse Lung Dis. 2012; 29: 41–50.

100 Troy LC, Corte TJ. Sleep disordered breathing in interstitial lung disease: a review. World J. Clin Cases 2014; 2: 828–34.

101 Trakada G, Nikolau E, Pouli A, Tsiamita M, Spiropoulos K. Sleep oxygen desaturation predicts survival in idiopathic pulmonary fibrosis. J. Clin. Sleep Med. 2013; 9: 593–601.

102 Clark M, Cooper B, Singh S, Cooper M, Carr A, Hubbard R. A survey of nocturnal hypoaxemia and health related quality of life in patients with cryptogenic fibrosing alveolitis. Thorax 2001; 56: 482–6.

103 Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, Minai OA, Ricaurte B, Kw...
Kitaguchi Y, Fujimoto K, Hanaoka M, Honda T, Hotta J, Hirayama J. Pulmonary function impairment in patients with combined pulmonary fibrosis and emphysema with and without airflow obstruction. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9: 805–11.

Jankowich MD, Rounds S. Combined pulmonary fibrosis and emphysema alters physiology but has similar mortality to pulmonary fibrosis without emphysema. Lung 2010; 188: 365–73.

Mejia M, Carrillo G, Rojas-Serrano J, Estrada A, Suarez T, Alonso D, Barrientos E, Gaziola M, Navarro C, Selman M. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009; 136: 10–5.

Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie-Leblond I, Israel-Biet D, Court-Fortune I, Valeyre D, Cordier JF; Groupe d’Etude et de Recherche sur les Maladies Orphelines Pulmonaires (GERM O P). Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur. Respir. J. 2005; 26: 586–93.

Kwak N, Park CM, Lee J, Park YS, Lee SM, Yim JJ, Yoo CG, Kwak N, Park CM, Lee J, Park YS, Lee SM, Yim JJ, Yoo CG. Interstitial lung disease. Am. J. Respir. Crit. Care Med. 2015; 191: 1501–8.

Cortez M, Cottin V, Taniguchi H, Richeldi L, Collard H, Kaye M, Hansell D, Bailes Z, Schlenker-Hercog R, Raghu G. Effect of baseline emphysema on resolution in FVC decline with nintedanib in the INPULSIS trials. Respirology 2015; 20: 57.

De Vries W, Adir Y, Barbera JA, Champion H, Coghan JG, Cottin V, de Marco T, Galie N, Ghio S, Gibbs S et al. Pulmonary hypertension in chronic lung disease. J. Am. Coll. Cardiol. 2013; 62: D109–16.

Hook JL, Arcasoy SM, Zemmel D, Bartels MN, Kawut SM, Lederer DJ. Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis. Eur. Respir. J. 2012; 39: 359–65.

Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003; 168: 538–42.

Egan TM, Murray S, Bustami RT, Shearon TH, McCullough KP, Edwards LB, Coke MA, Garrity ER, Sweet SC, Heiney DA et al. Development of the new lung allocation system in the United States. Am. J. Transplant. 2006; 6: 1212–27.

Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1: 681–6.

Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann. Intern. Med. 1980; 93: 91–8.

McDonald CF, Crockett AJ, Young IH. Adult domiciliary oxygen therapy. Position statement of the Thoracic Society of Australia and New Zealand. Med. J. Aust. 2005; 182: 621–6.

McDonald CF, Whyte K, Jenkins S, Sergisson J, Frith P. Clinical practice guideline on adult domiciliary oxygen therapy: executive summary from the Thoracic Society of Australia and New Zealand. Respirology 2016; 21: 76–8.

Bye PT, Anderson SD, Woolcock AJ, Young IH, Alison JA. Bicycle endurance performance of patients with interstitial lung disease breathing air and oxygen. Am. Rev. Respir. Dis. 1982; 126: 1005–12.

Harris-Eze AO, Sridhar G, Clemens RE, Gallagher CG, Marciniuk DD. Oxygen improves maximal exercise performance in interstitial lung disease. Am. J. Respir. Crit. Care Med. 1994; 150: 1616–22.

Visca D, Montgomery A, de Lauretis A, Sestini P, Soteriou H, Maher TM, Wells AJ, Renzoni EA. Ambulatory oxygen in interstitial lung disease. Eur. Respir. J. 2011; 38: 987–90.

Frank RC, Hicks S, Duck AM, Spencer L, Leonard CT, Barnett E. Ambulatory oxygen in idiopathic pulmonary fibrosis: of what benefit? Eur. Respir. J. 2012; 40: 269–70.

Nishiyama O, Miyajima H, Fukai Y, Yamazaki R, Satoh R, Yamagata T, Sano H, Iwanaga T, Higashimoto Y, Nakajima H et al. Effect of ambulatory oxygen on exertional dyspnea in IPF patients without resting hypoxemia. Respir. Med. 2013; 107: 1241–6.

Chaouat A, Weitenblum E, Kessler R, Charpentier C, Enhart M, Schott R, Levi-Valensi P, Zielinski J, Denuaonis L, Cornudella R et al. A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients. Eur. Respir. J. 1999; 14: 1002–6.

Fletcher EC, Luckett RA, Goodnight-White S, Miller CC, Qian W, Costarangos-Galarza C. A double-blind trial of nocturnal supplemental oxygen for sleep desaturation in patients with chronic obstructive pulmonary disease and a daytime PaO2 above 60 mm Hg. Am. Rev. Respir. Dis. 1992; 145: 1070–6.

Shea SA, Winning AJ, McKenzie E, Guz A. Does the abnormal pattern of breathing in patients with interstitial lung disease persist in deep, non-rapid eye movement sleep? Am. Rev. Respir. Dis. 1989; 139: 653–8.

Vazquez JC, Perez-Padilla R. Effect of oxygen on sleep and breathing in patients with interstitial lung disease at moderate altitude. Respiration 2001; 68: 584–9.

Crockett AJ, Cranston JM, Antic N. Domiciliary oxygen for interstitial lung disease. Cochrane Database Syst. Rev. 2001; CD002883.

Downon I, Hill CJ, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst. Rev. 2014; 10: CD006322.

Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 2008; 63: 549–54.

Vainshelboim B, Oliveira J, Fox BD, Soreck Y, Fruchter O, Kramer MR. Long-term effects of a 12-week exercise training program on clinical outcomes in idiopathic pulmonary fibrosis. Lung 2015; 193: 345–54.

Holland AE, Hill CJ, Glaspole I, Goh N, McDonald CF. Predictors of benefit following pulmonary rehabilitation for interstitial lung disease. Respir. Med. 2012; 106: 429–35.

Spruit MA, Singh SJ, Garvey C, ZuiWallack R, Nici L, Rochester C, Hill K, Holland AE, Lareau SC, Man WD et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am. J. Respir. Crit. Care Med. 2013; 188: e13–64.

Alison JA, McKeough ZJ, Johnston K, McNamara RJ, Spencer LM, Jenkins SC, Hill CJ, McDonald VM, Frith P, Cafarella P et al.; on behalf of the Lung Foundation Australia and the Thoracic Society of Australia and New Zealand. Australian and New Zealand pulmonary rehabilitation guidelines. Respirology 2017; 22: 800–19.

Keating A, Lee A, Holland AE. What prevents people with chronic obstructive pulmonary disease from attending pulmonary rehabilitation? A systematic review. Chron. Respir. Dis. 2011; 8: 89–99.

Holland AE, Fiore JR Jr, Goh N, Symons K, Downon L, Westall G, Hazard A, Glaspole I. Be honest and help me prepare for the future: what people with interstitial lung disease want from education in pulmonary rehabilitation. Chron. Respir. Dis. 2015; 12: 93–101.

Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, Lederer DJ, Mulligan MJ, Patterson GA, Singer LG et al. A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J. Heart Lung Transplant. 2015; 34: 1–15.

Organ Procurement and Transplantation Network. 2016. [Accessed May 2017.] Available from URL: http://optn.transplant.hrsa.gov/

Bennett D, Fossi A, Bargagli E, Refini RM, Pieroni M, Luzzi L, Ghiribelli C, Paladini P, Voloniti L, Rottoli P. Mortality on the waiting list for lung transplantation in patients with idiopathic...
pulmonary fibrosis: a single-centre experience. *Lung* 2015; 193: 677–81.

149 Yusen RD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Goldfarb SB, Levey BI, Lund LH, Meiser B, Rossano JW et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-Second Official Adult Lung and Heart-Lung Transplantation Report—2015; focus theme: early graft failure. *J. Heart Lung Transplant*. 2015; 34: 1264–77.

150 Grimm JC, Valero V 3rd, Magruder JT, Kilic A, Dungan SP, Silhnan LL, Shah PD, Kim BS, Merlo CA, Sciortino CM et al. A novel risk model incorporating recipient and donor demographics to predict 1-year mortality in the current era of lung transplantation. *J. Heart Lung Transplant*. 2015; 34: 1449–54.

151 Thabut G, Christie JD, Ravaud P, Castier Y, Dauriat G, Jebbak G, Fournier M, Lesche G, Porcher R, Mal H. Survival after bilateral versus single-lung transplantation for idiopathic pulmonary fibrosis. *Ann. Intern. Med.* 2009; 151: 767–74.

152 Schaffer JM, Singh SK, Reitz BA, Zamanian RT, Mallidi HR. Single- vs double-lung transplantation in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis since the implementation of lung allocation based on medical need. *JAMA* 2015; 313: 936–48.

153 Bajwah S, Higginson IJ, Ross JR, Wells AU, Birring SS, Patel A, Riley J. The palliative care needs for fibrotic interstitial lung disease: a qualitative study of patients, informal caregivers and health professionals. *Palliat. Med.* 2013; 27: 869–76.

154 Danoff SK, Schonhoff EH. Role of support measures and palliative care. *Curr. Opin. Pulm. Med.* 2013; 19: 480–4.

155 Lanken PN, Terry PB, Delisser HM, Fahy BF, Hansen-Flaschen J, Heffner JE, Levy M, Mularski RA, Osborne ML, Prendergast TJ et al. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. *Am. J. Respir. Crit. Care Med.* 2008; 177: 912–27.

156 Bajwah S, Ross JR, Wells AU, Mohammed K, Oyebode C, Birring SS, Patel AS, Koffman J, Higginson IJ, Riley J. The palliative care for patients with advanced fibrotic lung disease: a randomised controlled phase II and feasibility trial of a community care conference intervention. *Thorax* 2015; 70: 830–9.

157 Garibaldi BT, Danoff SK. Symptom-based management of the idiopathic interstitial pneumonias. *Respirology* 2016; 21: 1357–65.

158 Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadley KE. A systematic review of the use of opioids in the management of dyspnoea. *Thorax* 2002; 57: 939–44.

159 Abernethy AP, Currow DC, Frith P, Fazeekas BS, McHugh A, Bui C. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. *BMJ* 2003; 327: 523–8.

160 Kohberg C, Andersen CU, Bendstrup E. Opioids: an unexplored option for treatment of dyspnea in IPF. *Eur. Clin. Respir. J.* 2016; 3: 30629.

161 Ekstrom MP, Abernethy AP, Currow DC. The management of chronic breathlessness in patients with advanced and terminal illness. *BMJ* 2015; 349: g7617.

162 Simon ST, Higginson IJ, Booth S, Harding R, Weingartner V, Bausewein C. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. *Cochrane Database Syst. Rev.* 2016; 10: CD007354.

163 Abernethy AP, McDonald CF, Frith PA, Clark K, Herndon JE 2nd, Marcello J, Young IH, Bull J, Wilcoock A, Booth S et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. *Lancet* 2010; 376: 784–93.

164 Campbell MJ, Yarandi H, Dove-Medows E. Oxygen is nonbeneficial for most patients who are near death. *J. Pain Symptom Manage.* 2013; 45: 517–23.

165 Brown KK. Chronic cough due to chronic interstitial pulmonary diseases: ACCP evidence-based clinical practice guidelines. *Chest* 2006; 129: 1806–5a.

166 Lee JS, McLaughlin S, Collard HR. Comprehensive care of the patient with idiopathic pulmonary fibrosis. *Carr. Opin. Pulm. Med.* 2011; 17: 348–54.

167 Horton MR, Danoff SK, Lechtzin N. Thalidomide inhibits the intractable cough of idiopathic pulmonary fibrosis. *Thorax* 2008; 63: 749.

168 Bajwah S, Koffman J, Higginson IJ, Ross JR, Wells AU, Birring SS, Riley J. ‘I wish I knew more …’ the end-of-life planning and information needs for end-stage fibrotic interstitial lung disease: views of patients, carers and health professionals. *BMJ Support. Palliat. Care* 2013; 3: 84–90.

169 Bajwah S, Higginson IJ, Ross JR, Wells AU, Birring SS, Patel A, Riley J. Specialist palliative care is more than drugs: a retrospective study of ILD patients. *Lung* 2012; 190: 215–20.

170 Lindell KO, Liang Z, Hoffman LA, Roszenzweig MQ, Saul MI, Pilewski JM, GibsonKF, Kaminski N. Palliative care and location of death in decedents with idiopathic pulmonary fibrosis. *Chest* 2015; 147: 423–9.

171 Ahmad Z, Wysham NG, Lundstrom S, Janson C, Currow DC, Ekstrom M. End-of-life care in oxygen-dependent ILD compared with lung cancer: a national population-based study. *Thorax* 2016; 71: S10–6.

172 Beernaert K, Cohen J, Deliexi I, Derooy E, Vanthomme K, Pardon K, Van den Block L. Referral to palliative care in COPD and other chronic diseases: a population-based study. *Respir. Med.* 2013; 107: 1731–9.

173 Brown CE, Jecker NS, Curtis JR. Inadequate palliative care in chronic lung disease. An issue of health care inequality. *Ann. Am. Thorac. Soc.* 2016; 13: 311–6.

174 Wachterman MW, Pilev C, Smith D, Ersek M, Lipsitz SR, Keating NL. Quality of end-of-life care provided to patients with different serious illnesses. *JAMA Intern. Med.* 2016; 176: 1095–102.

175 Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admans M, Jackson VA, Dahlbin CM, Blinderman CD, Jacobsen J, Pirl WF et al. Early palliative care for patients with metastatic non-small-cell lung cancer. *N. Engl. J. Med.* 2010; 363: 733–42.

176 Duck A, Spencer LG, Bailey S, Leonard C, Ormes J, Caress AL. Perceptions, experiences and needs of patients with idiopathic pulmonary fibrosis. *J. Adv. Nurs.* 2015; 71: 1055–65.

177 Collard HR, Tino G, Noble PW, Shreve MA, Michaels M, Carlson B, Schwarz MI. Patient experiences with pulmonary fibrosis. *Respir. Med.* 2007; 101: 1359–64.

178 Schoenheit G, Becattelli I, Cohen AH. Living with idiopathic pulmonary fibrosis: an in-depth qualitative survey of European patients. *Chron. Respir. Dis.* 2011; 8: 225–31.

179 Morisset J, Dupe BP, Garvey C, Bourbeau J, Collard HR, Swigis JJ, Lee JS. The unmet educational needs of patients with interstitial lung disease. Setting the stage for tailored pulmonary rehabilitation. *Ann. Am. Thorac. Soc.* 2016; 13: 1026–33.

180 Lindell KO, Ohshansky E, Song MK, Zullo TG, GibsonKF, Kaminski N, Hoffman LA. Impact of a disease-management program on symptom burden and health-related quality of life in patients with idiopathic pulmonary fibrosis and their care partners. *Heart Lung* 2010; 39: 304–13.

181 Duck A, Pigram L, Erhardt P, Ahmed D, Chauhduri N. IPF Care: a support program for patients with idiopathic pulmonary fibrosis treated with pirfenidone in Europe. *Adv. Ther.* 2015; 32: 87–107.

182 Australia Lung Foundation. Patient support – idiopathic pulmonary fibrosis. [Accessed 16 Sep 2016.] Available from URL: http://lungfoundation.com.au/patient-support/rarelung/idiopathic-pulmonary-fibrosis/igf/.

183 Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, Lindell KO, Silveira LJ, Linelll KO, Steele MP, Loyd JE et al. Association ...
between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. *JAMA* 2013; **309**: 2232–9.

186 Stuart BD, Lee JS, Kozlitina J, Noth I, Devine MS, Glazer CS, Torres F, Kaza V, Girod CE, Jones KD *et al*. Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. *Lancet Respir. Med.* 2014; **2**: 557–65.

187 Newton CA, Batra K, Torrealba J, Kozlitina J, Glazer CS, Aravena C, Meyer K, Raghu G, Collard HR, Garcia CK. Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. *Eur. Respir. J.* 2016; **48**: 1710–20.

188 Oldham JM, Ma SF, Martinez FJ, Anstrom KJ, Raghu G, Schwartz DA, Valenzi E, Witt L, Lee C, Vij R *et al*. TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. *Am. J. Respir. Crit. Care Med.* 2015; **192**: 1475–82.

**Supplementary Information**

Additional supplementary information can be accessed via the html version of this article at the publisher’s website.

**Appendix S1 Disclosure statement.**